Hubchak SC, Sparks EE, Hayashida T, Schnaper HW. Rac1 promotes TGF-␤-stimulated mesangial cell type I collagen expression through a PI3K/Akt-dependent mechanism.
TRANSFORMING GROWTH FACTOR (TGF)-␤ is a multifunctional cytokine that has been linked to proliferation, apoptosis, differentiation, and fibrosis (21, 34) . In renal systems, TGF-␤ is profibrotic in experimental models of glomerular disease such as diabetic nephropathy (38) . Additionally, overexpressing TGF-␤ induces glomerulosclerosis in transgenic mice (36) . As part of its profibrotic role, TGF-␤ enhances expression of extracellular matrix (ECM) proteins such as fibronectin and collagen in glomerular mesangial cells (24, 32) . TGF-␤ also induces epithelial-to-mesenchymal transition (EMT) in several tissues (6) . In the kidney, TGF-␤ causes tubular cells to acquire a more fibrogenic phenotype, migrate to interstitial spaces, and secrete a type I collagen-rich matrix (45) .
Members of the TGF-␤ family signal through a heterotetrameric, transmembrane serine/threonine kinase receptor complex. Upon ligand binding, the receptor complex recruits the receptor-regulated Smads (R-Smads), which become phosphorylated and form heteromultimeric complexes with the common partner Smad (Smad4) (18) . The Smad complex then translocates to the nucleus where it regulates gene transcription by direct binding to DNA and/or interaction with other transcription factors (22) . Although TGF-␤ signaling is dependent on Smad family protein activity, other signaling molecules, including those regulating cytoskeletal function, have been implicated in fibrotic signaling (15) . Among these is the Rho family of small GTPases. These molecules function as switch proteins, alternating between an active, GTP-bound, and an inactive, GDP-bound state. The three most studied members of the Rho-GTPase family are RhoA, Rac1, and Cdc42. RhoA has been implicated in stress fiber formation, Rac1 in lamellipodia formation, and Cdc42 in filopodia formation (9) . The activation of RhoA (4, 23) , Rac1 (1, 26) , and Cdc42 (16, 41) by TGF-␤ is cell type specific (4) . In renal epithelial cells, all three have been shown to play a role in EMT (30) , and RhoA has been found to be necessary for the TGF-␤ induction of smooth muscle ␣-actin (␣-SMA) in several cell types (4, 23) . Another signaling molecule, phosphatidylinositol-3-kinase (PI3K), is also activated by TGF-␤ and has been shown to enhance Smad3-stimulated collagen expression in human mesangial cells (HMC) (35) and to be required for EMT (2) . PI3K activity may also modulate or be modulated by members of the RhoGTPase family (2, 40) .
We previously showed that treatment with C. difficile toxin B, a nonspecific inhibitor of Rho-GTPases, or Y27632, an inhibitor of the downstream effector of RhoA, Rho-kinase (ROK) abrogates the TGF-␤ induction of type I collagen in HMC (20) . In the present study, we sought to examine activation of RhoA and Rac1 by TGF-␤ in HMC and how they might contribute to renal fibrogenesis. Our data indicate that in HMC, while RhoA and Rac1 are both activated by TGF-␤, only Rac1 contributes to type I collagen accumulation, and it does so in a manner that requires active PI3K.
MATERIALS AND METHODS

Materials.
Active recombinant human TGF-␤1 was purchased from R&D Systems (Minneapolis, MN) and reconstituted to 4 g/ml in 4 mM HCl containing 1 mg/ml bovine serum albumin. Mouse anti-RhoA (1:500) and mouse anti-Rac1 (1:250) were purchased from Cytoskeleton (Denver, CO). Mouse anti-Smad 1/2/3 (1:2,000) and goat anti-Smad2/3 (1 g/500 g protein) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit anti-Smad3 (1:250) and rabbit anti-phosphoserine were purchased from Invitrogen/Zymed (South San Francisco, CA). Rabbit anti-phospho-Smad3 (1:1,000), rabbit anti-phospho Akt (1:1,000), and rabbit anti-Akt (1:1,000) were purchased from Cell Signaling (Beverly, MA). SB431542 (5 M), NSC23766 (50 -100 M), LY294002 (LY; 20 M), and C3 transferase (C3T; 0.1-1 g/ml) were purchased from Calbiochem/EMD Biosciences (La Jolla, CA); some lots of C3T were purchased from Cytoskeleton, and PDGF-BB (10 ng/ml) was obtained from PeproTech (Rocky Hill, NJ).
Plasmid constructs. The -378COL1A2-LUC construct containing the sequence of 378 bp of the ␣2(I) collagen promoter and 58 bp of the transcribed sequence fused to the luciferase reporter gene (LUC) was constructed as previously described (31) . The ␣-SMA-LUC construct containing the mouse ␣-SMA promoter fused to LUC was a gift from Dr. R. J. Schwartz (Baylor College of Medicine, Houston, TX) (25) . The Smad binding element (SBE)-LUC reporter was a gift from Dr. B. Vogelstein (44) . Dominant-negative (dn) N19RhoA and N17Rac1 and constitutively active (ca) L61Rac1, cloned into a pRK5 Myc vector, were kindly provided by Dr. A. Hall (University College London, London, UK). The FHRE-Luc reporter construct (8) was purchased from Addgene (Cambridge, MA; Addgene plasmid 1789).
Cells. HMC were isolated from glomeruli of normal renal cortex as described previously (37) and determined to be mycoplasma negative by the method of Chen (12) . Cells were cultured in DMEM/F12 medium supplemented with 16% heat-inactivated newborn calf serum (NBCS) or 10% cosmic calf serum (CCS) obtained from Hyclone (Logan, UT), glutamine, penicillin/streptomycin, sodium pyruvate, HEPES buffer, and 8 g/ml insulin (Sigma, St. Louis, MO) and were used between passages 5 and 8.
Treatments. For C3T experiments, 1/10 volume FuGene6 was first incubated in DMEM/F12 for 5 min at room temperature. Indicated amounts of C3T DMEM:F12 were incubated with diluted FuGene6 for 15 min at room temperature. The resulting complexes were diluted to 10 g/ml FuGene6 with serum-free mesangial medium, added to the cells, and incubated at 37°C for 4 h before stimulation with 1 ng/ml TGF-␤1. Cells were pretreated with NSC23766 or SB431542 as indicated in the figure legends before administration of 1 ng/ml TGF-␤1. After treatments, cells were harvested for immunoprecipitation and Western analysis as previously described (35) .
Rho and Rac activation assays. RhoA and Rac1 activation was assessed using commercially available kits from Cytoskeleton, according to the manufacturer's instructions, with modifications. HMC were grown to near confluence and serum deprived 18 -24 h before treatment with 1 ng/ml TGF-␤1 and/or inhibitors. Cells were harvested using provided lysis buffer containing protease inhibitors and centrifuged to remove insoluble material. To detect active RhoA, equal volumes of clarified lysates from 150-mm dishes were incubated with 5 g of the Rho-GTP binding domain (RBD) of the rhotekin protein bound to GST beads for 1 h at 4°C. The beads were washed once in lysis buffer followed by two washes with the kit's wash buffer. To detect active Rac1, 400 -500 g of clarified lysates were incubated with 10 g of the Rac/Cdc42 binding domain (PBD) of p21-activated kinase (PAK) protein bound to GST beads for 1 h at 4°C. The beads were then washed with the provided wash buffer. To release bound proteins, the beads were briefly boiled in 2ϫ Laemelli buffer. Active GTP-Rho, GTP-Rac, and whole cell lysates were subjected to electrophoresis on 15% acrylamide gels and analyzed via Western blot techniques, as previously described (35) .
RNA isolation and Northern blot. Total RNA was isolated with TRIzol (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions and analyzed via Northern blot techniques as previously described (35) . cDNA for human ␣1(I) chain (clone Hf677) (7) was obtained from Dr. Y. Yamada (National Institutes of Health, Bethesda, MD). The signal obtained from hybridization with a bovine cDNA for 18S or 28S rRNA (the latter obtained from Dr. H. Sage, University of Washington, Seattle, WA) was used to correct for loading.
Transient transfection. For reporter assays, cells were plated in triplicate per condition at 1-1.5 ϫ 10 5 cells per well in six-well dishes. The following day, the medium was changed to 1 ml per well of 1% NBCS or CCS-containing mesangial medium and transfected with 0.5 g of DNA of each of the indicated constructs along with 0.5 g of CMV-SPORT-␤-galactosidase (Invitrogen) as a control for transfection efficiency. Transfection was performed using FuGene6 transfection reagent (Roche Applied Science, Indianapolis, IN) as previously described (31) . Three hours posttransfection, cells were treated with control vehicle or 1 ng/ml TGF-␤1, harvested at 18 -24 h, and then assayed for luciferase and ␤-galactosidase activities with kits purchased from Promega (Madison, WI).
F-actin detection. Cells were grown on gelatin-coated coverslips and fixed with warm 3.7% formaldehyde in 60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 3 mM MgCl2, 0.2% Triton X-100, pH 6.1, for 10 min. F-actin was detected using rhodamine phalloidin (Cytoskeleton) according to the manufacturer's directions. Slides were mounted with AquaPolymount (Polysciences, Warrington, PA). Fluorescent images of NSC23766-treated cells were obtained using an Axiovert 100M confocal microscope with a Plan apochromat 63ϫ/1.4 oil objective and LSM510 Version 3.2 SP1 software; images of C3T-treated cells were obtained using an Axiovert 200M confocal microscope with a Neofluar 40ϫ/1.3 oil objective and LSM510 Version 4.2 SP1 software (Zeiss, Thornwood, NY). Digital images were converted to TIFF files and a figure was prepared using Adobe Photoshop.
Statistical analysis. Densitometric values of bands obtained from Western or Northern blots were quantified using the NIH Image 1.61 or ImageJ program for Macintosh. Statistical significance was determined using a two-tailed, two-sample, equal variance Student's t-test (Microsoft Excel) or a two-way ANOVA with Bonferroni posttests (GraphPad Prism version 4.0 for Macintosh, GraphPad Software, San Diego, CA; http://www.graphpad.com), as described in the legends, with P Ͻ 0.05 considered significant.
RESULTS
TGF-␤ rapidly activates RhoA and Rac1 and requires active ALK5/TGF-␤ receptor type I.
Previously, we reported that toxin B, an inhibitor of the Rho family of small GTPases, and Y27632, an inhibitor of the RhoA effector Rho kinase, block TGF-␤1-stimulated type I collagen mRNA expression (20) . To determine the kinetics of RhoA and Rac1 activation by TGF-␤1 in HMC, active forms of RhoA or Rac1 were pulled down with sequences from rhotekin or PAK, respectively. Activation of both RhoA and Rac1 was apparent within 5 min of TGF-␤1 treatment (Fig. 1A, top) and analysis of total cellular RhoA and Rac1 (bottom) confirmed equal protein expression. We found that the time of peak RhoA or Rac1 activity in this assay varies from 5 to 30 min between experiments (data not shown). To determine whether activation of RhoA or Rac1 by TGF-␤ requires the kinase activity of the TGF-␤ receptor, we treated cells with TGF-␤1 in the presence or absence of the ALK5/TGF-␤ receptor type I (T␤RI) kinase inhibitor, SB431542 (SB4). SB4 blocked TGF-␤1-stimulated RhoA (Fig. 1B , top 2 panels) or Rac1 (middle 2 panels) activity. To confirm blockade of ALK5/T␤RI activity, signaling downstream of T␤R, indicated by Smad3 phosphorylation after TGF-␤1 treatment, was abrogated in the presence of the inhibitor (Fig. 1B, bottom 2 panels) . Thus, TGF-␤1 rapidly stimulates activity of both RhoA and Rac1 and this activation requires ALK5/T␤RI kinase activity.
Rac1 mediates TGF-␤1-stimulated collagen I expression. To examine the potential roles of RhoA and Rac1 in fibrogenesis, we investigated the accumulation of ECM after TGF-␤1 treatment, using as our marker mRNA expression and promoter activity of type I collagen. TGF-␤1-stimulated ␣1(I) collagen mRNA expression was assessed in the pres-ence of the exoenzyme C3T, an inhibitor of Rho isoforms, or NSC23766, an inhibitor of Rac1 activation. Since we reported that the ROK inhibitor Y27632 blocked TGF-␤1-stimulated ␣1(I) collagen expression (20), we were surprised that C3T failed to block the TGF-␤1-stimulated increase in steady-state expression of ␣1(I) collagen mRNA ( Fig. 2A) . To determine the efficacy of C3T treatment, we stained cells with rhodamine phalloidin, a dye that specifically binds to polymerized actin. Cells treated with C3T exhibited an overall decrease in staining intensity and a marked reduction in intact stress fibers, consistent with blockade of Rho isoform activity (Fig. 2C) , confirming the efficacy of this inhibitor. In contrast, NSC23766 reduced the fold induction of collagen I mRNA in response to TGF-␤1 mRNA 19% at 50 M and 68% at 100 M (Fig. 2B) , but had no effect on stress fiber architecture (Fig. 2D) . To determine the effect of Rac1 on collagen gene activation, COL1A2 promoter activity was assessed in the presence or absence of constitutively active L61Rac1 (caRac1) or dn N17Rac1 (dnRac1) constructs (Fig. 3) . TGF-␤1 stimulation of the collagen promoter in the presence of the empty vector (pRK5) resulted in a 2.5-to 3.5-fold induction of activity (Fig. 3, A, B , and C). Transfection with dnRac1 significantly reduced TGF-␤1 induction of the COL1A2 promoter (Fig.  3A) , while transfection with ca Rac1 increased induction 2.5-fold over that with empty vector (Fig. 3B) . In contrast, dnRhoA had no effect on promoter induction (Fig. 3C) . These results indicate that Rac1 participates in the TGF-␤1 induction of type I collagen, while RhoA activity and intact stress fibers are not required.
Rac1 does not directly affect TGF-␤-stimulated Smad3 activity. To determine whether TGF-␤-stimulated Rac1 activity enhances type I collagen expression through the Smad signaling pathway, we examined the effect of blocking Rac1 activity on Smad3 activation. Treatment of cells with the Rac1 inhibitor, NSC23766, failed to block TGF-␤-stimulated COOH-terminal Smad3 phosphorylation, as detected by an antibody specific for phospho-serine residues at 423 and 425 (Fig. 4A) . Because phosphorylation at additional serine/threonine sites could affect R-Smad function, lysates were immunoprecipitated with anti-Smad2/3 and blotted for phospho-serine to access total phosphorylation, and both Smad2 and 3 were found to be similarly unaffected by inhibitor treatment (data not shown). Since Smad3 binding to the SBE in the COL1A2 promoter is also required for TGF-␤-mediated collagen I transcription (11), it is possible that TGF-␤-stimulated Rac1 activity could lead to increased binding of Smad3 to the SBE and consequent increased transcription. When HMC were transfected with empty vector or dnRac1 and treated with TGF-␤, we saw no significant difference in induction of SBE-LUC reporter activity (Fig. 4B) . Since blocking Rac1 does not reduce the activation or transcriptional activity of Smad3, taken together, these results suggest that Rac1 does not enhance the collagen response through a direct effect on Smad3 signaling.
TGF-␤-activated Rac1 requires PI3K activity to enhance type I collagen expression. Previously, we reported that TGF-␤ activates PI3K in HMC and enhances the collagen response (35) . Others showed that PI3K can lead to Rac1 activation and that active Rac1 can itself activate PI3K (40) . To determine whether PI3K activity is required for TGF-␤-stimulated Rac1 activation in HMC, we pretreated cells with LY, a PI3K inhibitor, or DMSO and then stimulated them with TGF-␤1 before determining active Rac1 levels. LY pretreatment reduced TGF-␤1-stimulated Rac1 activity 85% at 5 min and 60% at 30 min compared with DMSO-treated controls (Fig. 5) . To ascertain whether TGF-␤-stimulated Rac1 activity itself results in PI3K activity that could enhance collagen expression, we transfected HMC with caRac1 in the presence or absence of LY and evaluated the effect of TGF-␤1 treatment on COL1A2 promoter activity. In cells transfected with pRK5 [empty vector (EV)], TGF-␤ induced a 2.5-fold increase in promoter activity (Fig. 6 ). caRac1 alone increased basal promoter activity 3.2-fold, comparable to that of TGF-␤-stimulated, EV-transfected cells. With TGF-␤ stimulation, cells transfected with caRac1 showed a 22-fold increase in promoter activity (6.8-fold over basal) that was 2.7 times that observed in control conditions. LY reduced basal and TGF-␤-stimulated promoter activities in EVtransfected cells to a net 1.5-fold increase. Although LY reduced both basal and stimulated promoter activity in caRac1- transfected cells, TGF-␤ still induced a 2.6-fold increase of collagen promoter activity over vehicle-treated cultures. To determine the effect of increased Rac1 activity on the PI3K effector Akt, we transfected HMC with a construct containing a portion of the Fas ligand promoter comprised of three Forkhead response elements coupled to a luciferase reporter gene (FHRE-luc). Under serum deprivation, FKHRL1, a member of the Forkhead family of transcription factors, resides in the nucleus where it can activate gene transcription. Growth factor treatment or transfection with caAkt raises phospho-Akt levels, leading to phosphorylation of FKHRL1, its retention in the cytoplasm, and loss of reporter activity (8) . In cells transfected with EV, TGF-␤1 reduced FHRE-luc activity by 46% (Fig. 6B) . Transfection of cells with caRac1 alone reduced expression levels 51%, with little further reduction seen on TGF-␤1 treatment. Cells treated with PDGF-BB served as a positive control for Akt activation, as indicated by reduced FHRE-Luc activity. Taken together, these data suggest that PI3K activity is required for TGF-␤ activation of Rac1 and that this activation of Rac1 itself leads to further PI3K activation.
DISCUSSION
A role has been suggested for the Rho family GTPases in renal fibrogenesis (28, 30) . In the present study, we found that TGF-␤1 rapidly activates both RhoA and Rac1 in HMC via an ALK5/T␤RI-dependent mechanism. Rac1, but not RhoA, activity enhanced TGF-␤1-induced type I collagen expression through a mechanism that did not directly alter canonical Smad3 signaling events. Rac1 did require PI3K activity for full activation after TGF-␤1 stimulation and active Rac1 could itself stimulate activity of Akt, the downstream effector of PI3K. Thus, we propose that TGF-␤1 activates Rac1 via T␤R1-activated PI3K and that activated Rac1 can subsequently further stimulate PI3K activity in a potential positive feedback loop (Fig. 7) . Since inhibition of PI3K did not totally prevent TGF-␤1-stimulated COL1A2 promoter activity, and PI3K alone does not induce promoter activity (35) , the present findings suggest that Smad3 activity is the primary activator of the collagen gene, with Rac1/PI3K playing an enhancing role.
The Rho-GTPases RhoA, Rac1, and Cdc42 have been shown to be involved in the formation of stress fibers, laemellapodia and filopodia, respectively, but each has been shown to mediate other nonstructural events as well (3, 5, 33) . Previously, we reported that disrupting the actin cytoskeleton with cytochalasin D or the nonspecific Rho-GTPase inhibitor, toxin B, blocked the TGF-␤1 induction of steady-state collagen I mRNA in HMC. Inhibiting one of the downstream effectors of RhoA, ROK, with Y27632 maintained cell shape but reduced stress fiber formation and abrogated TGF-␤1-stimulated collagen I expression (20) . These results suggested that RhoA activity and actin cytoskeletal structure are important for TGF-␤-mediated collagen I expression. Here, we find that directly inhibiting Rho isoform activity in HMC with C3T significantly decreases actin stress fiber formation, but has no effect on TGF-␤-stimulated steady-state collagen I mRNA expression, nor does transfection with dnRhoA block TGF-␤ induction of COL1A2 promoter activity. In contrast, blocking Rac1 activity with the inhibitor NSC23766 has no effect on stress fiber structure, but does inhibit TGF-␤-stimulated steady-state collagen I mRNA expression. We speculate that in the case of cytochalasin D and toxin B, TGF-␤1-stimulated collagen I expression was decreased due to the impact of gross cytoskeletal disruption on Rac1-dependent effects, such as cell spreading (14) .
ROK activity is commonly interpreted as an indicator of Rho activity, and ROK inhibitors have been shown to ameliorate glomerular injury in models of hypertension (28) and to prevent tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction (UUO) (27) . However, no protection from fibrosis was seen in ROK␤ (ROCK1)-null UUO mice (19) , so it could be that Y27632 acts through non-ROK-related mechanisms. In view of our previous observation that ROK inhibition decreases the collagen response to TGF-␤ in our cells, and our present finding that direct RhoA inhibition does not decrease this response, our results also raise the possibility of Rho-independent ROK activation (17) or ROK-dependent Rac1 activation (42) . It is also possible that in our in vitro system, the activities of other RhoA effectors not blocked by Y27632 unexpectedly affect TGF-␤-stimulated collagen expression. RhoA activity plays a central role in TGF-␤-mediated upregulation of ␣-SMA, considered to be a marker of a switch to a fibrogenic phenotype in renal diseases (23) . In our studies, blocking RhoA activity with C3T or dnRhoA blocked TGF-␤ induction of ␣-SMA mRNA and promoter activity, respectively; Rac1 inhibition had no effect on TGF-␤-stimulated ␣-SMA mRNA expression or promoter activity (data not shown). Together, our data suggest that in HMC, TGF-␤ initiates both stress fiber-related (␣-SMA upregulation) and Fig. 7 . TGF-␤ potentially activates a Rac1-positive feedback loop to enhance type 1 collagen expression. We propose that Rac1 is activated by TGF-␤ through T␤R-activated PI3K. GTP-Rac1 then appears to further stimulate PI3K activity, which could then enhance Smad3-mediated type I collagen transcription by an as yet undetermined mechanism. stress fiber-independent (collagen accumulation) fibrogenic programs.
We did not detect an effect of Rac1 blockade on TGF-␤1-stimulated COOH-terminal Smad3 phosphorylation. Furthermore, we found no difference in SBE-Luc activation by TGF-␤1 after cotransfecting EV or dnRac1. We thereby conclude that it is unlikely that Rac1 increases TGF-␤1-stimulated collagen expression through a direct effect on Smad signaling. TGF-␤ signaling in a Smad-independent manner through the PI3K pathway has been observed (15) . PI3Ks, a family of proteins that phosphorylate the 3Ј-hydroxyl group on the inositol ring of phosphoinositides, can be activated by TGF-␤ directly through the T␤R (43) or indirectly via transactivation of receptor tyrosine kinases (15) . We previously showed that crosstalk between the Smad and PI3K signaling pathways enhances TGF-␤-stimulated type I collagen expression (35) . Since other groups showed that PI3K can both activate Rac1 via guanine nucleotide exchange factors (GEFs) and be activated by GTP-Rac1 through a GTPase-responsive domain in the p85 subunit (10, 40), we examined the role of PI3K in the Rac1 enhancement of TGF-␤1-stimulated collagen induction. Treatment of cells with the PI3K inhibitor, LY, reduced TGF-␤1-stimulated Rac1 activity by 85% at 5 min and 60% at 30 min, suggesting that PI3K plays an important upstream role in Rac1 activation. We speculate that the less profound inhibition at 30 min could reflect competing signals that enhance TGF-␤-stimulated Rac1 activity in a PI3K-independent manner. Conversely, HMC transfected with caRac1 showed increased basal and stimulated COL1A2 promoter activity that was partially blocked by LY treatment. The fact that some residual COL1A2 promoter response remained despite the presence of LY suggests that Smad3 alone can mediate some promoter activation, but that this response is considerably enhanced by PI3K/Akt signaling. Indeed, since Rac1 inhibition reduces COL1A2-Luc activation but not SBE-Luc activation by TGF-␤1, our data suggest that the more complex collagen promoter requires the additional participation of Rac1-dependent transcription factors that are not required for SBE activity.
We also noted that TGF-␤1 reduced the expression of a Fas ligand-luciferase promoter construct known to be negatively affected by phosphoAkt. caRac1 alone reduced the activity of this promoter as much as TGF-␤1 did in EV-transfected cells. TGF-␤1 treatment did not further reduce FHRE-luc activity in caRac1-transfected cells. Since caRac1 alone repressed promoter activity to almost the same extent as the positive control for pAkt stimulation, PDGF-BB, it is possible that PI3K is maximally stimulated by caRac1. Taken together, these data suggest that Rac1, once activated by PI3K, can further activate PI3K in a potential positive feedback loop.
As GTP-Rac1 forms a part of and is required for NADPH oxidase activity, we speculated that generation of reactive oxygen species (ROS) could also play a role in enhancing collagen expression. Recently, it has been reported that integrin ␣1-null mesangial cells produce excessive ROS through a Rac1-dependent mechanism that leads to collagen IV accumulation (13) . However, in our hands, NADPH oxidase-selective antioxidants failed to significantly block TGF-␤1-stimulated collagen expression (data not shown).
Another factor to consider is the nature of the ECM that cells are in contact with. It is noteworthy that culturing cells on type I collagen may induce elements of EMT, including TGF-␤ expression and increased collagen I expression in response to TGF-␤ (29) , and may in fact stimulate Rac1 activity via PI3K activation (39) . Thus, the findings in the present report may constitute part of an amplification pathway for renal cell fibrogenesis. Our studies were performed in HMC cultured on plastic plates. While this condition does not duplicate the microenvironment that is present in vivo, it should be noted that our practice of permitting the cells to achieve quiescence on this plastic substrate also allows time for the cells to secrete at least a provisional matrix that could include type I collagen. Therefore, we cannot comment definitively regarding the nature of the substratum to which the cells are attached, but speculate that it may play a role in fostering the sclerotic response to TGF-␤.
In summary, we propose that, while TGF-␤1 activates both RhoA and Rac1 in HMC, these GTPases mediate different responses that could contribute to glomerular scar formation. TGF-␤-stimulated GTP-Rac1 appears to enhance type I collagen expression through a PI3K-dependent/stress fiber-independent mechanism. The diversity of signaling pathways in different portions of the fibrogenic program emphasizes the importance of targeting specific pathways to interrupt progressive renal scarring.
